Global News

Patheon to acquire Banner Pharmacaps

Tuesday, October 30, 2012 10:24 AM

Patheon, a Durham, N.C.-based provider of contract development and manufacturing services, has signed a definitive agreement with Vion, a global manufacturer of foodstuffs and ingredients based in the Netherlands, to acquire Banner Pharmacaps, a High Point, N.C.-based specialty pharmaceutical business dedicated to the research, development and manufacturing of unique gelatin-based dosage forms.

More... »

Amgen, KPCB partner to create new spin-out biotech

Friday, October 26, 2012 02:43 PM

Amgen, a biotech based in Thousand Oaks, Calif., and Kleiner Perkins Caufield & Byers (KPCB), a venture capital firm, have created Atara Biotherapeutics, a new drug development company with a focus on innovative therapies for patients with chronic diseases in therapeutic areas including nephrology and oncology.

More... »

Shire’s Angus Russell to retire in 2013, Ornskov to succeed as CEO

Friday, October 26, 2012 12:07 PM

The board of directors of Shire, a global specialty biopharmaceutical company based in Ireland, has announced the retirement in 2013 of chief executive Angus Russell after 13 years with the company and 32 years in the pharmaceutical industry.

More... »

Thrasos secures $35M for THR-184 phase II program for acute kidney injury

Friday, October 26, 2012 11:39 AM

Thrasos Therapeutics, a Canadian clinical stage biotherapeutics company, has completed a $35 million financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).

More... »

Seattle Genetics, Abbott expand antibody-drug conjugate collaboration

Wednesday, October 24, 2012 11:02 AM

Seattle Genetics, a Bothell, Wash.-based biotech focused on monoclonal antibody-based therapies for the treatment of cancer, has expanded its antibody-drug conjugate (ADC) collaboration with Abbott Laboratories, a global healthcare company.

More... »

Forest Laboratories, moksha8 form strategic alliance for Latin America

Wednesday, October 24, 2012 10:33 AM

Forest Laboratories, an international pharmaceutical company, and moksha8, a pharmaceutical company that commercializes CNS medicines in Latin America, have entered into a broad strategic alliance that will provide Forest with a commercial footprint in Latin America and give moksha8 access to Viibryd and potentially other Forest products for the Latin American market.

More... »

Lilly touts positive results from phase III trials of dulaglutide in T2D

Monday, October 22, 2012 01:24 PM

Global pharmaceutical company Eli Lilly released positive top-line results of three completed phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes.

More... »

Pfizer to acquire NextWave Pharmaceuticals

Monday, October 22, 2012 12:56 PM

Pfizer, a global research-based pharmaceutical company, has agreed to acquire NextWave Pharmaceuticals, a privately-held, specialty pharmaceutical company focused on attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders.

More... »

AMRI, Shire ink 5-year extension of API supply agreement

Monday, October 22, 2012 12:22 PM

AMRI, a global contract research and manufacturing organization, has entered into a multi-year supply agreement for an undisclosed product with Shire U.S. Manufacturing, a subsidiary of specialty biopharmaceutical company Shire.

More... »

Alnylam, Genzyme to develop and commercialize RNAi therapeutics in Asia

Monday, October 22, 2012 12:01 PM

Alnylam Pharmaceuticals, a biopharmaceutical company based in Cambridge, Mass., and Genzyme, a Sanofi company, have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

More... »